ASTH Stock Forecast & Price Target

Astrana Health is bullish due to their strong management team, partnerships with major payers, expected increases in base, diagnosis source, and risk model revision, and effective technology systems, as well as utilizing AI to reduce costs and potential for growth. The recent acquisition of Prospect Medical is seen as a good fit and expected to contribute to revenue and earnings, with potential for a 5%+ increase in MA reimbursement in 2027E and margin expansion through improved RAF scores and measures being implemented. Overall, analysts rate ASTH as a Buy with potential risks to consider.

Astrana Health is a patient-centered, physician-centric integrated population health management company, but it faces significant competition from larger companies in the value-based healthcare space. There is also potential financial risk if Medicare reimbursement does not increase as expected in the future. Additionally, while the company has demonstrated success and growth in its current markets, expanding into new states may prove to be a challenging and costly endeavor. Overall, Astrana's financial outlook may be impacted by its competition, changes in healthcare policies, and the success of its expansion efforts.